These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20833330)

  • 21. Clinical manifestations of familial medullary thyroid carcinoma.
    Kameyama K; Okinaga H; Takami H
    Biomed Pharmacother; 2004; 58(6-7):348-50. PubMed ID: 15271414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the role of RET polymorphisms/haplotypes as modifier loci for MEN 2, and analysis of the correlation with the type of RET mutation in a series of Spanish patients.
    Fernández RM; Navarro E; Antiñolo G; Ruiz-Ferrer M; Borrego S
    Int J Mol Med; 2006 Apr; 17(4):575-81. PubMed ID: 16525712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double germline mutations in the RET Proto-oncogene in MEN 2A and MEN 2B kindreds.
    Dvorakova S; Vaclavikova E; Ryska A; Cap J; Vlcek P; Duskova J; Kodetova D; Holub V; Novak Z; Bendlova B
    Exp Clin Endocrinol Diabetes; 2006 Apr; 114(4):192-6. PubMed ID: 16705552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A rare extracellular D631Y germline mutation of the RET proto-oncogene in two Korean families with multiple endocrine neoplasia 2A.
    Bae SJ; Kim DJ; Kim JY; Park SY; Choi SH; Song YD; Ki CS; Chung JH
    Thyroid; 2006 Jun; 16(6):609-14. PubMed ID: 16839264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10.
    Frank-Raue K; Rybicki LA; Erlic Z; Schweizer H; Winter A; Milos I; Toledo SP; Toledo RA; Tavares MR; Alevizaki M; Mian C; Siggelkow H; Hüfner M; Wohllk N; Opocher G; Dvořáková S; Bendlova B; Czetwertynska M; Skasko E; Barontini M; Sanso G; Vorländer C; Maia AL; Patocs A; Links TP; de Groot JW; Kerstens MN; Valk GD; Miehle K; Musholt TJ; Biarnes J; Damjanovic S; Muresan M; Wüster C; Fassnacht M; Peczkowska M; Fauth C; Golcher H; Walter MA; Pichl J; Raue F; Eng C; Neumann HP;
    Hum Mutat; 2011 Jan; 32(1):51-8. PubMed ID: 20979234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].
    Ito T; Shirahama S; Ogura K; Yamamoto S; Takami H
    Nihon Rinsho; 2004 May; 62(5):883-8. PubMed ID: 15148813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
    Kameyama K; Okinaga H; Takami H
    Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One hundred and seven family members with the rearranged during transfection V804M proto-oncogene mutation presenting with simultaneous medullary and papillary thyroid carcinomas, rare primary hyperparathyroidism, and no pheochromocytomas: is this a new syndrome--MEN 2C?
    Shifrin AL; Xenachis C; Fay A; Matulewicz TJ; Kuo YH; Vernick JJ
    Surgery; 2009 Dec; 146(6):998-1005. PubMed ID: 19958926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nationwide French Study of RET Variants Detected from 2003 to 2013 Suggests a Possible Influence of Polymorphisms as Modifiers.
    Lebeault M; Pinson S; Guillaud-Bataille M; Gimenez-Roqueplo AP; Carrie A; Barbu V; Pigny P; Bezieau S; Rey JM; Delvincourt C; Giraud S; Veyrat-Durebex C; Saulnier P; Bouzamondo N; Chabbert M; Blin J; Mohamed A; Romanet P; Borson-Chazot F; Rohmer V; Barlier A; Mirebeau-Prunier D
    Thyroid; 2017 Dec; 27(12):1511-1522. PubMed ID: 28946813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
    Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Multiple endocrine neoplasia type 2].
    Sheu SY; Schmid KW
    Pathologe; 2010 Oct; 31(6):449-54. PubMed ID: 20960196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation.
    Mian C; Barollo S; Zambonin L; Pennelli G; Bernante P; Pelizzo MR; Nacamulli D; Mantero F; Girelli ME; Opocher G
    Fam Cancer; 2009; 8(4):379-82. PubMed ID: 19475497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A.
    Schulte KM; Machens A; Fugazzola L; McGregor A; Diaz-Cano S; Izatt L; Aylwin S; Talat N; Beck-Peccoz P; Dralle H
    J Clin Endocrinol Metab; 2010 Sep; 95(9):E92-7. PubMed ID: 20554711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization.
    Castellone MD; Verrienti A; Magendra Rao D; Sponziello M; Fabbro D; Muthu M; Durante C; Maranghi M; Damante G; Pizzolitto S; Costante G; Russo D; Santoro M; Filetti S
    Clin Endocrinol (Oxf); 2010 Oct; 73(4):529-34. PubMed ID: 20039896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report.
    Menon MM; Simha MR
    Indian J Pathol Microbiol; 2005 Apr; 48(2):161-5. PubMed ID: 16758654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple endocrine neoplasia type 2.
    Marini F; Falchetti A; Del Monte F; Carbonell Sala S; Tognarini I; Luzi E; Brandi ML
    Orphanet J Rare Dis; 2006 Nov; 1():45. PubMed ID: 17105651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.
    Yip L; Cote GJ; Shapiro SE; Ayers GD; Herzog CE; Sellin RV; Sherman SI; Gagel RF; Lee JE; Evans DB
    Arch Surg; 2003 Apr; 138(4):409-16; discussion 416. PubMed ID: 12686527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Composite phaeochromocytoma-ganglioneuroblastoma in a patient with multiple endocrine neoplasia type IIA.
    Matias-Guiu X; Garrastazu MT
    Histopathology; 1998 Mar; 32(3):281-2. PubMed ID: 9568520
    [No Abstract]   [Full Text] [Related]  

  • 40. Dermal Hyperneury and Multiple Sclerotic Fibromas in Multiple Endocrine Neoplasia Type 2A Syndrome.
    Alegría-Landa V; Jo-Velasco M; Robledo M; Requena L
    JAMA Dermatol; 2017 Dec; 153(12):1298-1301. PubMed ID: 29049491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.